FyMed Heralds Breakthrough in the Treatment of Colon Cancer with Novel Drug Candidate FY405B
FyMed is advancing targeted candidates for both early and advanced colorectal cancer. FY405B is an investigational cancer targeted cytotoxic therapy, a new class of treatments that use the body's own selective pathways to help fight cancer. FyMed has developed substantial preclinical evidence that its drug candidate, FY405B, could effectively kill colon cancer cells through in-vitro studies as well as in animal models of colon cancer.
View full press release